

## FORM 7

### MONTHLY PROGRESS REPORT

Name of Listed Issuer: MustGrow Biologics Corp. (the "Issuer").

Trading Symbol: MGRO

Number of Outstanding Listed Securities: 41,987,186

Date: February 2, 2021

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

#### **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**The Issuer is an agricultural biotech company focused on developing and commercializing a portfolio of patented natural biopesticides including its patented signature mustard-derived biologic, targeting the fruit & vegetable industry.**

**During the period the Issuer focused on the following:**

- **Continuing research and development studies for the Company's bio pesticide/herbicide/fungicide products.**
- **Advancing regulatory filings and approvals for the Company's bio pesticide/herbicide/fungicide products.**
- **On January 14, 2021, the Company issued a press release announcing receipt of over \$1.5 million from the exercise of warrants.**
- **On January 19, 2021, the Company issued a press release confirming positive soil health and ecological impact of its natural mustard-derived biopesticide.**
- **On January 20, 2021, the Company issued a press release announcing test results of its mustard-derived biopesticide, achieving 100% control of a root-rot disease.**

2. Provide a general overview and discussion of the activities of management.

**During the period, management was primarily focused on the activities detailed in section 1 as well as exploring other strategic initiatives in the agriculture pesticide industry.**

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**Not applicable during this period.**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**Not applicable during this period.**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**Not applicable during this period.**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**Not applicable during this period.**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**Not applicable during this period.**

8. Describe the acquisition of new customers or loss of customers.

**Not applicable during this period.**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**The Issuer continued development of its intellectual property portfolio, including but not limited to, prosecution of its pending patent applications.**

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

**Not applicable during this period.**

11. Report on any labour disputes and resolutions of those disputes if applicable.

**Not applicable during this period.**

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**Not applicable during this period.**

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**Not applicable during this period.**

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds
Common Shares	1,494,337	Exercise of Warrants	Research and development and corporate operations

15. Provide details of any loans to or by Related Persons.

**None.**

16. Provide details of any changes in directors, officers or committee members.

**None.**

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

**The Issuer’s biopesticide product and technologies have application to the agriculture industry, which involves regulatory and market risks unique and inherent to that sector.**

**The outbreak of the Coronavirus disease (“COVID-19”) has resulted in governments worldwide enacting emergency measures to combat the spread of the virus. These measures, which include the implementation of travel bans, self-imposed quarantine periods and social distancing, have caused material disruption to businesses globally resulting in an economic slowdown. The duration and impact of the COVID-19 outbreak is not known at this time, nor is the efficacy of the government and central bank monetary and fiscal interventions designed to stabilize economic conditions. As a result, it is not possible to reliably estimate the length and severity of these developments or the impact on the financial position and financial results of the Company in future periods.**


## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated February 2, 2021.

Corey Giasson  
Name of Director or Senior  
Officer

  
\_\_\_\_\_  
Signature  
Director & CEO  
Official Capacity

<b>Issuer Details</b> Name of Issuer  MustGrow Biologics Corp	For Month End 2021-01-31	Date of Report YY/MM/D 21/02/02
Issuer Address 1005 – 201 1 <sup>st</sup> Avenue S.		
City/Province/Postal Code Saskatoon, SK S7K 1J5	Issuer Fax No. (306) 651 1931	Issuer Telephone No. (306) 668 2652
Contact Name Corey Giasson	Contact Position Director & CEO	Contact Telephone No. (306) 652 2652
Contact Email Address coreyg@mustgrow.ca	Web Site Address www.mustgrow.ca	